Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616834 | 0.81 | KDM4E (0.77) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL11187544 | 0.77 | KDM4E (0.53) | KDM4ETDP1TP53L3MBTL1ALOX15 | |
| SCHEMBL1704219 | 0.77 | KDM4E (0.69) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL11613627 | 0.77 | KDM4E (0.57) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL5361682 | 0.75 | KDM4E (0.55) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL18895753 | 0.74 | KDM4E (0.59) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL9756610 | 0.74 | GRM5 (0.60) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL9565604 | 0.73 | KDM4E (0.53) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL18905446 | 0.73 | KDM4E (0.63) | KDM4ETDP1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL5846342 | 0.73 | KDM4E (0.57) | KDM4ETDP1TP53ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | GENZYME | 2006-08-03 | — | — | US | disclosed |
| US-7034031-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | disclosed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | KDM4E 4319/4885TDP1 3193/4885TP53 4343/4885 |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | TNF, TNFRSF1A, CD40 | KDM4E 3837/4885TDP1 2531/4885TP53 491/4885 |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4252/4885TDP1 3459/4885TP53 2636/4885 |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4252/4885TDP1 3459/4885TP53 2636/4885 |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4252/4885TDP1 3459/4885TP53 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.